Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eluminate-5: elecoglipron plus dapagliflozin versus elecoglipron alone or dapagliflozin alone in adults with type 2 diabetes mellitus
2025-523941-81-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of elecoglipron and dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline to Week 40 in HbA1c. Planned start Aug 2026; status: authorised.
02
Drugs
elecogliprondapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-523941-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523941-81-00.